Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...

Novo Nordisk on Wednesday reported better-than-expected 2023 earnings, as sales of its wildly popular anti-obesity and diabetes drugs continued to soar. The maker of weight loss drug Wegovy and ...

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with ...

KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% ...

Avicenna.ai SAS received U.S. FDA clearance for its Cina-Cspine algorithm, which uses machine learning technology to detect ...

New data from Novo Nordisk’s phase 3 trial of an oral ... survodutide 4.8 mg versus 4.3% of controls. There was one red flag in the data, however; namely, that around a quarter (24.6%) of ...

FIRST IN PLAYBOOK — Senate Majority Leader CHUCK SCHUMER and House Minority Leader HAKEEM JEFFRIES are scheduled to attend a Congressional Gold Medal ceremony tomorrow honoring the 13 servicemembers ...

Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early-stage study, joining ...

Wednesday's edition of Forbes Daily covers TikTok whistleblower claims, the S&P's latest high, Trump's new crypto venture, ...

Nonetheless, it's a big green flag for the biotech's stock that a hungry giant like Novo Nordisk is willing to make such a substantial financial commitment to see what it can do. Similarly ...

This undated photo provided by Novo Nordisk shows flags bearing the company's logo. (Novo Nordisk via AP) (Uncredited, © Martin Nordmark) A drug approved to treat ...